Related Experiment Video
Updated: May 28, 2026
06:24
Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
Published on: December 15, 2017
Glycoprotein production in moss bioreactors
1Plant Biotechnology, University of Freiburg, Schaenzlestr. 1, 79104 Freiburg, Germany.
Plant Cell Reports
|October 1, 2011
Summary
Transgenic moss (Physcomitrella patens) offers a plant-based system for producing therapeutic antibodies. Engineered moss strains create non-immunogenic antibodies with enhanced efficacy compared to mammalian cell-produced versions.
Area of Science:
- Biotechnology
- Molecular Biology
- Biopharmaceutical Production
Background:
- Eukaryotic expression systems are essential for complex recombinant proteins like therapeutic antibodies.
- Plant-based systems are explored as alternatives to mammalian cell lines, offering similar post-translational modifications, including N-glycosylation.
- Plant-specific glycans can elicit immune responses, hindering the use of plants for biopharmaceutical production.
Purpose of the Study:
- To evaluate the moss Physcomitrella patens as a flexible system for producing recombinant biopharmaceuticals.
- To engineer the glycosylation machinery in P. patens to avoid immunogenic plant-specific glycan structures.
- To compare the efficacy of therapeutic antibodies produced in engineered moss strains versus mammalian cell lines.
Main Methods:
- Utilized P. patens in photobioreactors for contained production and secretion of recombinant proteins.
- Employed an efficient gene targeting mechanism to engineer the glycosylation pathway in P. patens.
- Synthesized therapeutic proteins, including a scFv antibody fragment and complement regulator factor H, in engineered moss lines.
- Assessed N-glycosylation patterns and antibody-dependent cellular cytotoxicity (ADCC) of produced antibodies.
Main Results:
- Demonstrated the versatility of P. patens for producing complex therapeutic proteins.
- Successfully created P. patens lines with optimized, non-immunogenic glycan structures through precise gene targeting.
- Therapeutic antibodies produced in engineered P. patens exhibited superior antibody-dependent cellular cytotoxicity compared to those from mammalian cell lines.
Conclusions:
- Physcomitrella patens is a viable and versatile platform for the contained production of recombinant biopharmaceuticals.
- Engineering the glycosylation pathway in P. patens can overcome the immunogenicity issue associated with plant-based glycan structures.
- P. patens-derived therapeutic antibodies show enhanced functional activity, presenting a promising alternative for biopharmaceutical manufacturing.
Related Concept Videos
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:30Designing Growth Media for Bioreactors
Growth media provide essential nutrients that support cell growth and metabolism, thereby enhancing the yield of valuable products such as enzymes, antibiotics, and biomass. Designing an effective growth medium involves balancing all components to prevent nutrient limitations or toxic excesses, both of which can impair growth and reduce product yields.Composition of a Typical Growth MediumA typical growth medium contains carbon and nitrogen sources, salts, vitamins, trace elements, and...
01:22Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...